GlobeNewswire: Atossa Therapeutics, Inc. Contains the last 10 of 194 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T08:32:05ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/19/2848557/0/en/Atossa-Therapeutics-Provides-Five-Year-Z-Endoxifen-Treatment-Update-on-FDA-Approved-Expanded-Access-Program-for-a-U-S-Breast-Cancer-Patient.html?f=22&fvtc=4&fvtv=36256Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient2024-03-19T12:30:00Z<![CDATA[SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-), breast cancer patient who received neoadjuvant and adjuvant (Z)-endoxifen therapy under an FDA-approved "expanded access" program has completed five years of treatment. As of the date of this press release, the patient remains cancer-free and has reported no significant safety or tolerability issues over the course of her treatment. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.]]>https://www.globenewswire.com/news-release/2024/03/18/2847774/0/en/Atossa-Therapeutics-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Listing-Requirements.html?f=22&fvtc=4&fvtv=36256Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements2024-03-18T12:30:00Z<![CDATA[SEATTLE, March 18, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that on March 15, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, with a focus on using (Z)-endoxifen to prevent and treat breast cancer.]]>https://www.globenewswire.com/news-release/2024/03/12/2844524/0/en/Atossa-Therapeutics-Appoints-Breast-Cancer-Specialist-Tessa-Cigler-M-D-M-P-H-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=36256Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors2024-03-12T12:30:00Z<![CDATA[SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Tessa Cigler, M.D., M.P.H. was appointed to Atossa’s board of directors, effective immediately. Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City.]]>https://www.globenewswire.com/news-release/2024/03/06/2841433/0/en/Data-from-Atossa-s-Phase-2-EVANGELINE-Clinical-Trial-to-be-Presented-at-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html?f=22&fvtc=4&fvtv=36256Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting2024-03-06T13:30:00Z<![CDATA[SEATTLE, March 06, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced today that data from the 40mg pharmacokinetic (PK) run-in cohort of the ongoing Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California. The EVANGELINE study is investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women diagnosed with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer.]]>https://www.globenewswire.com/news-release/2024/02/22/2833693/0/en/Atossa-Therapeutics-Announces-First-Patient-Dosing-of-Z-Endoxifen-in-the-Ongoing-RECAST-DCIS-Study.html?f=22&fvtc=4&fvtv=36256Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study2024-02-22T13:30:00Z<![CDATA[SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announced that the first patient has been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS) study. RECAST DCIS is an ongoing Phase 2 platform study designed to offer women diagnosed with DCIS six months of neoadjuvant endocrine therapy with the intent of determining their suitability for long-term active surveillance without surgery.]]>https://www.globenewswire.com/news-release/2024/02/07/2825198/0/en/Atossa-Therapeutics-Announces-Full-Enrollment-of-Z-Endoxifen-Arm-of-I-SPY-2-Clinical-Trial.html?f=22&fvtc=4&fvtv=36256Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial2024-02-07T13:30:00Z<![CDATA[SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that the (Z)-endoxifen arm of the ongoing Phase 2 I-SPY 2 clinical trial has fully enrolled. In the study, (Z)-endoxifen, Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), is being evaluated as a neoadjuvant treatment for newly diagnosed estrogen receptor-positive (ER+) invasive breast cancer.]]>https://www.globenewswire.com/news-release/2024/01/09/2806291/0/en/Atossa-Therapeutics-Issues-Letter-to-Shareholders.html?f=22&fvtc=4&fvtv=36256Atossa Therapeutics Issues Letter to Shareholders2024-01-09T13:30:00Z<![CDATA[SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:]]>https://www.globenewswire.com/news-release/2023/12/04/2790025/0/en/Atossa-Therapeutics-Announces-the-Appointment-of-Arezoo-Mirad-M-D-as-Senior-Medical-Director.html?f=22&fvtc=4&fvtv=36256Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director2023-12-04T13:30:00Z<![CDATA[SEATTLE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced the appointment of Dr. Arezoo Mirad as Senior Medical Director.]]>https://www.globenewswire.com/news-release/2023/11/20/2783241/0/en/Atossa-Therapeutics-Announces-Full-Enrollment-of-Phase-2-Karisma-Endoxifen-Clinical-Trial.html?f=22&fvtc=4&fvtv=36256Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial2023-11-20T13:30:00Z<![CDATA[SEATTLE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that it has reached full enrollment in the Company’s Karisma-Endoxifen clinical trial, the 240-person Phase 2 study investigating (Z)-endoxifen in premenopausal women with measurable mammographic breast density (MBD). Participants have been randomized to placebo, 1 mg, and 2 mg daily doses of (Z)-endoxifen and will be treated for six months, over the course of which mammograms are conducted to measure reduction in MBD. MBD change is used as a proxy for therapy response.]]>https://www.globenewswire.com/news-release/2023/11/13/2779093/0/en/Atossa-Therapeutics-Announces-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=36256Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update2023-11-13T14:00:00Z<![CDATA[SEATTLE, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces financial results for the quarter ended September 30, 2023, and provides an update on recent company developments.]]>